FLT3 and acute myeloid leukemia: This multicentric retrospective study evaluated the efficacy of gilteritinib in a cohort of 171 adult patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) harboring a FLT3 mutation, who had previously received at least two lines of therapy.